<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id><journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id><journal-id journal-id-type="publisher-id">JAH3</journal-id><journal-id journal-id-type="hwp">ahaoa</journal-id><journal-title-group><journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title></journal-title-group><issn pub-type="epub">2047-9980</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26672080</article-id><article-id pub-id-type="pmc">4845287</article-id><article-id pub-id-type="doi">10.1161/JAHA.115.002546</article-id><article-id pub-id-type="publisher-id">JAH31246</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group subj-group-type="heading"><subject>Coronary Heart Disease</subject></subj-group></subj-group></article-categories><title-group><article-title>Efficacy and Safety of Vorapaxar in Non&#x02013;<styled-content style="fixed-case">ST</styled-content>&#x02010;Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery</article-title><alt-title alt-title-type="left-running-head">van Diepen et&#x000a0;al</alt-title></title-group><contrib-group><contrib id="jah31246-cr-0001" contrib-type="author" corresp="yes"><name><surname>van Diepen</surname><given-names>Sean</given-names></name><degrees>MD, MSc</degrees><xref ref-type="aff" rid="jah31246-aff-0001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="jah31246-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31246-cr-0002" contrib-type="author"><name><surname>Tricoci</surname><given-names>Pierluigi</given-names></name><degrees>MD, PhD, MHS</degrees><xref ref-type="aff" rid="jah31246-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jah31246-cr-0003" contrib-type="author"><name><surname>Podder</surname><given-names>Mohua</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah31246-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31246-cr-0004" contrib-type="author"><name><surname>Westerhout</surname><given-names>Cynthia M.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="jah31246-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jah31246-cr-0005" contrib-type="author"><name><surname>Aylward</surname><given-names>Philip E.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31246-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jah31246-cr-0006" contrib-type="author"><name><surname>Held</surname><given-names>Claes</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="jah31246-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah31246-cr-0007" contrib-type="author"><name><surname>Van de Werf</surname><given-names>Frans</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31246-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="jah31246-cr-0008" contrib-type="author"><name><surname>Strony</surname><given-names>John</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31246-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="jah31246-cr-0009" contrib-type="author"><name><surname>Wallentin</surname><given-names>Lars</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31246-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="jah31246-cr-0010" contrib-type="author"><name><surname>Moliterno</surname><given-names>David J.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31246-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="jah31246-cr-0011" contrib-type="author"><name><surname>White</surname><given-names>Harvey D.</given-names></name><degrees>DSc</degrees><xref ref-type="aff" rid="jah31246-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="jah31246-cr-0012" contrib-type="author"><name><surname>Mahaffey</surname><given-names>Kenneth W.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31246-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="jah31246-cr-0013" contrib-type="author"><name><surname>Harrington</surname><given-names>Robert A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31246-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="jah31246-cr-0014" contrib-type="author"><name><surname>Armstrong</surname><given-names>Paul W.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="jah31246-aff-0002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="jah31246-aff-0011">
<sup>11</sup>
</xref></contrib></contrib-group><aff id="jah31246-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Divisions of Critical Care and Cardiology</named-content><institution>University of Alberta</institution><named-content content-type="city">Edmonton</named-content><named-content content-type="country-part">Alberta</named-content><country country="CA">Canada</country></aff><aff id="jah31246-aff-0002"><label><sup>2</sup></label><named-content content-type="organisation-division">Canadian VIGOUR Centre</named-content><institution>University of Alberta</institution><named-content content-type="city">Edmonton</named-content><named-content content-type="country-part">Alberta</named-content><country country="CA">Canada</country></aff><aff id="jah31246-aff-0003"><label><sup>3</sup></label><named-content content-type="organisation-division">Duke Clinical Research Institute</named-content><institution>Duke University Medical Center</institution><named-content content-type="city">Durham</named-content><named-content content-type="country-part">NC</named-content></aff><aff id="jah31246-aff-0004"><label><sup>4</sup></label><named-content content-type="organisation-division">SAHMRI</named-content><institution>Flinders University and Medical Centre</institution><named-content content-type="city">Adelaide</named-content><country country="AU">Australia</country></aff><aff id="jah31246-aff-0005"><label><sup>5</sup></label><named-content content-type="organisation-division">Department of Medical Sciences</named-content><institution>Uppsala Clinical Research Center</institution><named-content content-type="city">Uppsala</named-content><country country="SE">Sweden</country></aff><aff id="jah31246-aff-0006"><label><sup>6</sup></label><named-content content-type="organisation-division">Department of Cardiology</named-content><institution>University of Leuven</institution><country country="BE">Belgium</country></aff><aff id="jah31246-aff-0007"><label><sup>7</sup></label><institution>Merck</institution><named-content content-type="city">Whitehouse Station</named-content><named-content content-type="country-part">NJ</named-content></aff><aff id="jah31246-aff-0008"><label><sup>8</sup></label><named-content content-type="organisation-division">Gill Heart Institute and Division of Cardiovascular Medicine</named-content><institution>University of Kentucky</institution><named-content content-type="city">Lexington</named-content><named-content content-type="country-part">KY</named-content></aff><aff id="jah31246-aff-0009"><label><sup>9</sup></label><named-content content-type="organisation-division">Green Lane Cardiovascular Service</named-content><institution>Auckland City Hospital</institution><named-content content-type="city">Auckland</named-content><country country="NZ">New Zealand</country></aff><aff id="jah31246-aff-0010"><label><sup>10</sup></label><institution>Stanford University</institution><named-content content-type="city">Stanford</named-content><named-content content-type="country-part">CA</named-content></aff><aff id="jah31246-aff-0011"><label><sup>11</sup></label><named-content content-type="organisation-division">Division of Cardiology</named-content><institution>University of Alberta</institution><named-content content-type="city">Edmonton</named-content><named-content content-type="country-part">Alberta</named-content><country country="CA">Canada</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence to:</bold> Sean van Diepen, MD, MSc, 2C2 Cardiology Walter MacKenzie Center, University of Alberta Hospital, 8440&#x02010;11 St. Edmonton, Alberta, Canada T6G 2B7. E&#x02010;mail: <email>sv9@ualberta.ca</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>12</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2015</year></pub-date><volume>4</volume><issue>12</issue><issue-id pub-id-type="doi">10.1002/jah3.2015.4.issue-12</issue-id><elocation-id>e002546</elocation-id><history><date date-type="received"><day>10</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>30</day><month>10</month><year>2015</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.</copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x02010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JAH3-4-e002546.pdf"/><abstract id="jah31246-abs-0001"><sec id="jah31246-sec-0001"><title>Background</title><p>Perioperative antiplatelet agents potentially increase bleeding after non&#x02013;<styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation (<styled-content style="fixed-case">NSTE</styled-content>) acute coronary syndromes (<styled-content style="fixed-case">ACS</styled-content>). The protease&#x02010;activated receptor 1 antagonist vorapaxar reduced cardiovascular events and was associated with increased bleeding versus placebo in <styled-content style="fixed-case">NSTE ACS</styled-content>, but its efficacy and safety in noncardiac surgery (<styled-content style="fixed-case">NCS</styled-content>) remain unknown. We aimed to evaluate ischemic, bleeding, and long&#x02010;term outcomes of vorapaxar in <styled-content style="fixed-case">NCS</styled-content> after <styled-content style="fixed-case">NSTE ACS</styled-content>.</p></sec><sec id="jah31246-sec-0002"><title>Methods and Results</title><p>In the <styled-content style="fixed-case">TRACER</styled-content> trial, 2202 (17.0%) patients underwent major or minor <styled-content style="fixed-case">NCS</styled-content> after <styled-content style="fixed-case">NSTE ACS</styled-content> over 1.5&#x000a0;years (median); continuing study treatment perioperatively was recommended. The primary ischemic end point for this analysis was cardiovascular death, myocardial infarction, stent thrombosis, or urgent revascularization within 30&#x000a0;days of <styled-content style="fixed-case">NCS</styled-content>. Safety outcomes included 30&#x02010;day <styled-content style="fixed-case">NCS</styled-content> bleeding and <styled-content style="fixed-case">GUSTO</styled-content> moderate/severe bleeding. Overall, 1171 vorapaxar and 1031 placebo patients underwent <styled-content style="fixed-case">NCS</styled-content>. Preoperative aspirin and thienopyridine use was 96.8% versus 97.7% (<italic>P</italic>=0.235) and 89.1% versus 86.1% (<italic>P</italic>=0.036) for vorapaxar versus placebo, respectively. Within 30&#x000a0;days of <styled-content style="fixed-case">NCS</styled-content>, no differences were observed in the primary ischemic end point between vorapaxar and placebo groups (3.4% versus 3.9%; adjusted odds ratio 0.81, 95% <styled-content style="fixed-case">CI</styled-content> 0.50 to 1.33, <italic>P</italic>=0.41). Similarly, no differences in <styled-content style="fixed-case">NCS</styled-content> bleeding (3.9% versus 3.4%; adjusted odds ratio 1.41, 95% <styled-content style="fixed-case">CI</styled-content> 0.87 to 2.31, <italic>P</italic>=0.17) or <styled-content style="fixed-case">GUSTO</styled-content> moderate/severe bleeding (4.2% versus 3.7%; adjusted odds ratio 1.15, 95% <styled-content style="fixed-case">CI</styled-content>, 0.72 to 1.83, <italic>P</italic>=0.55) were observed. In a 30&#x02010;day landmarked analysis, <styled-content style="fixed-case">NCS</styled-content> patients had a higher long&#x02010;term risk of the ischemic end point (adjusted hazard ratio 1.62, 95% <styled-content style="fixed-case">CI</styled-content> 1.33 to 1.97, <italic>P</italic>&#x0003c;0.001) and <styled-content style="fixed-case">GUSTO</styled-content> moderate/severe bleeding (adjusted hazard ratio 5.63, 95% <styled-content style="fixed-case">CI</styled-content> 3.98 to 7.97, <italic>P</italic>&#x0003c;0.001) versus patients who did not undergo <styled-content style="fixed-case">NCS</styled-content>, independent of study treatment.</p></sec><sec id="jah31246-sec-0003"><title>Conclusion</title><p>
<styled-content style="fixed-case">NCS</styled-content> after <styled-content style="fixed-case">NSTE ACS</styled-content> is common and associated with more ischemic outcomes and bleeding. Vorapaxar after <styled-content style="fixed-case">NSTE ACS</styled-content> was not associated with increased perioperative ischemic or bleeding events in patients undergoing <styled-content style="fixed-case">NCS</styled-content>.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jah31246-kwd-0001">coronary disease</kwd><kwd id="jah31246-kwd-0002">hemorrhage</kwd><kwd id="jah31246-kwd-0003">noncardiac surgery</kwd><kwd id="jah31246-kwd-0004">non&#x02013;<styled-content style="fixed-case">ST</styled-content>&#x02010;segment elevation acute coronary syndromes</kwd><kwd id="jah31246-kwd-0005">surgery</kwd><kwd id="jah31246-kwd-0006">vorapaxar</kwd></kwd-group><kwd-group kwd-group-type="subject-categories"><title>Subject Categories</title><kwd>Acute Coronary Syndromes</kwd></kwd-group><funding-group><award-group><funding-source>Merck &#x00026; Co, Inc</funding-source></award-group></funding-group><counts><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jah31246</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2015</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.8.4 mode:remove_FC converted:03.03.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jah31246-cit-1001">(<source>J Am Heart Assoc</source>. <year>2015</year>;<volume>4</volume>:e002546 doi: <ext-link ext-link-type="doi" xlink:href="10.1161/JAHA.115.002546">10.1161/JAHA.115.002546</ext-link>)</mixed-citation>
</p></notes><notes><fn-group id="jah31246-ntgp-0001"><fn id="jah31246-note-0001"><p>Accompanying Tables S1 through S4 are available at <ext-link ext-link-type="uri" xlink:href="http://jaha.ahajournals.org/content/4/12/e002546/suppl/DC1">http://jaha.ahajournals.org/content/4/12/e002546/suppl/DC1</ext-link>
</p></fn></fn-group></notes></front><body><sec id="jah31246-sec-0004"><title>Introduction</title><p>After an acute coronary syndromes (ACS) or percutaneous coronary interventions, up to one&#x02010;third of patients require noncardiac surgery (NCS).<xref rid="jah31246-bib-0001" ref-type="ref">1</xref>, <xref rid="jah31246-bib-0002" ref-type="ref">2</xref>, <xref rid="jah31246-bib-0003" ref-type="ref">3</xref> Importantly, a previous ACS is an important risk factor for perioperative major adverse cardiac events.<xref rid="jah31246-bib-0004" ref-type="ref">4</xref>, <xref rid="jah31246-bib-0005" ref-type="ref">5</xref>, <xref rid="jah31246-bib-0006" ref-type="ref">6</xref> Although the perioperative use of antiplatelet therapies has been reported to reduce major adverse cardiac events in high&#x02010;risk NCS patients, it may also increase bleeding complications.<xref rid="jah31246-bib-0007" ref-type="ref">7</xref>, <xref rid="jah31246-bib-0008" ref-type="ref">8</xref>, <xref rid="jah31246-bib-0009" ref-type="ref">9</xref>, <xref rid="jah31246-bib-0010" ref-type="ref">10</xref> In the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial, the protease&#x02010;activated receptor 1 antagonist vorapaxar reduced the secondary end point of cardiovascular death, myocardial infarction, or stroke but increased the risk of bleeding in patients with non&#x02013;ST&#x02010;segment elevation (NSTE) ACS.<xref rid="jah31246-bib-0011" ref-type="ref">11</xref> The long biologic half&#x02010;life of vorapaxar coupled with its recent US Food and Drug Administration regulatory approval for use in patients with a previous myocardial infarction without a previous stroke, transient ischemic attack, or intracranial bleeding creates unique questions regarding its optimal perioperative use. The efficacy and safety of vorapaxar in patients undergoing NCS after NSTE ACS have not been explored.<xref rid="jah31246-bib-0012" ref-type="ref">12</xref>
</p><p>Although the 30&#x02010;day perioperative risks and clinical outcomes in NCS have been described in the percutaneous coronary intervention era, the long&#x02010;term outcomes associated with major and minor NCS after NSTE ACS remain unclear.<xref rid="jah31246-bib-0001" ref-type="ref">1</xref>, <xref rid="jah31246-bib-0003" ref-type="ref">3</xref>, <xref rid="jah31246-bib-0013" ref-type="ref">13</xref>, <xref rid="jah31246-bib-0014" ref-type="ref">14</xref> Accordingly, in the TRACER trial, we evaluated (1) the 30&#x02010;day perioperative and long&#x02010;term efficacy and safety of vorapaxar in patients undergoing major and minor NCS as they relate to the type and timing of surgery and (2) the long&#x02010;term prognosis associated with NCS after NSTE ACS.</p></sec><sec id="jah31246-sec-0005"><title>Methods</title><p>The TRACER trial (ClinicalTrials.gov identifier NCT00527943) was a multicenter, double&#x02010;blind, randomized placebo&#x02010;controlled study that evaluated vorapaxar in 12&#x000a0;944 NSTE ACS patients in 37 countries. The methods and results of this study have been previously described.<xref rid="jah31246-bib-0011" ref-type="ref">11</xref>, <xref rid="jah31246-bib-0012" ref-type="ref">12</xref> Briefly, patients were enrolled if they presented to a hospital within 24&#x000a0;hours of coronary ischemia symptoms with &#x02265;1 of the following: creatinine kinase&#x02010;MB or troponin level higher than the upper limit of normal; new ST&#x02010;segment depression &#x0003e;0.1&#x000a0;mV; or transient (&#x0003c;30&#x000a0;minutes) ST&#x02010;segment elevation &#x0003e;0.1&#x000a0;mV in 2 contiguous leads. Patients also required &#x02265;1 of the following additional risk factors: age &#x02265;55&#x000a0;years; prior myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting; diabetes mellitus; or peripheral arterial disease. Randomized patients received vorapaxar or a matching placebo, and the intention to use a glycoprotein IIb/IIIa inhibitor and a parenteral direct thrombin inhibitor was stratified. The study was approved by the appropriate national and institutional regulatory and ethics committees, and all participants provided informed consent.</p><sec id="jah31246-sec-0006"><title>Study Population and Covariates</title><p>The present analysis included all patients in the TRACER trial who were admitted with an NSTE ACS and treated either with a coronary stent or with medical therapy alone and subsequently underwent either major or minor NCS. Patients who underwent coronary artery bypass grafting were specifically excluded: vorapaxar outcomes in this patient population have been previously described.<xref rid="jah31246-bib-0015" ref-type="ref">15</xref> The TRACER case report form contained the type, date, and reasons for NCS procedure as entered by local study personnel. The study authors examined all NCS data entries and classified them as either major or minor surgery. Major surgical procedures were defined using the American Heart Association/American College of Cardiology definitions of intermediate&#x02010; and high&#x02010;risk procedures.<xref rid="jah31246-bib-0016" ref-type="ref">16</xref> Major procedures were further classified by surgical site according to prior categorization as follows: abdominal, thoracic, orthopedic and spinal, vascular, pelvic (urological and gynecological), intracranial neurologic, and head and neck surgeries.<xref rid="jah31246-bib-0017" ref-type="ref">17</xref>, <xref rid="jah31246-bib-0018" ref-type="ref">18</xref>, <xref rid="jah31246-bib-0019" ref-type="ref">19</xref> Minor surgical procedures were similarly identified using guideline definitions of low&#x02010;risk procedures and included endoscopic, superficial, cataract, breast, ambulatory, percutaneous, or dental procedures.<xref rid="jah31246-bib-0016" ref-type="ref">16</xref> Repeat coronary angiograms, percutaneous coronary interventions, and cardiac surgical procedures were excluded. If a patient underwent a major and minor surgical procedure within 30&#x000a0;days, the major procedure was hierarchically selected as the index procedure to avoid an excess attributable risk to minor procedures (eg, a bronchoscopy preceding a lobectomy).</p><p>The timing of NCS after NSTE ACS events was a priori categorized as follows: &#x02264;30, &#x0003e;30 to 180, &#x0003e;180&#x000a0;days to 1&#x000a0;year, and &#x0003e;1&#x000a0;year. The TRACER case report form coded for the preoperative use of all cardiac medications. Given the long biologic half&#x02010;life of vorapaxar, the study protocol recommended study drug continuation through NCS procedures.<xref rid="jah31246-bib-0012" ref-type="ref">12</xref> The timing and reasons for interruptions were recorded in the case report form by local study personnel. The primary analysis of this study compared clinical end points in vorapaxar&#x02010; versus placebo&#x02010;treated patients who underwent NCS. A secondary analysis evaluated the long&#x02010;term clinical outcomes in NSTE ACS patients who underwent NCS regardless of treatment assignment. A sensitivity analysis limited to participants who were receiving perioperative treatment was also performed.</p></sec><sec id="jah31246-sec-0007"><title>Outcomes</title><p>The primary ischemic end point for this analysis was the incidence of 30&#x02010;day perioperative cardiovascular death, nonfatal myocardial infarction, stent thrombosis, or urgent revascularization. The secondary ischemic end points of interest included the TRACER trial primary end point (cardiovascular death, myocardial infarction, recurrent ischemia with rehospitalisation, or stroke), the individual components of the primary ischemic end point, all&#x02010;cause mortality, stroke, and the incidence of the composite primary outcome among 30&#x02010;day NCS survivors through study follow&#x02010;up. The primary bleeding end point was the 30&#x02010;day incidence of perioperative NCS bleeding defined as any GUSTO (Global Utilization of Strategies to Open Occluded Arteries) or TIMI (Thrombolysis In Myocardial Infarction) bleeding associated with the NCS. For example, a surgical incision site hematoma would qualify as NCS bleeding but spontaneous epistaxis would not. The secondary bleeding end points included all 30&#x02010;day perioperative GUSTO moderate or severe bleeding, TIMI major or minor bleeding, and TIMI clinical significant bleeding. All clinical end points were adjudicated by a clinical events committee.</p></sec><sec id="jah31246-sec-0008"><title>Statistical Methods</title><p>Patient and procedural characteristics, concomitant treatment, and in&#x02010;hospital procedures are reported as medians (25th, 75th percentiles) for continuous variables and as percentages for discrete variables. The Wilcoxon rank sum test and &#x003c7;<sup>2</sup> test were applied, respectively, to test differences between groups, including 30&#x02010;day outcomes. Kaplan&#x02013;Meier estimates were reported for 2&#x02010;year follow&#x02010;up, and differences among groups were tested by using the log&#x02010;rank test (when proportional hazard assumptions were met).</p><p>The associations of vorapaxar versus placebo with the 30&#x02010;day NCS primary end point and safety end points for the NCS patients (intent&#x02010;to&#x02010;treat) were examined through multivariable logistic regression. These associations were examined in patients who were event free at the time of surgery. Study treatment&#x02013;related analyses were based on the intention&#x02010;to&#x02010;treat assumption, unless otherwise stated. Associations with 30&#x02010;day events were reported as odds ratios (ORs) with 95% CIs. Sensitivity analyses were also carried out on patients who were receiving treatment during surgery, including 901 vorapaxar&#x02010; and 819 placebo&#x02010;treated patients.</p><p>To compare long&#x02010;term prognosis between NSTE ACS patients who did not undergo NCS with those who did undergo NCS and survived 30&#x000a0;days postrandomization and postoperatively, respectively, time&#x02010;to&#x02010;event analyses were performed. Hazard ratios (HRs) and 95% CIs were calculated using Cox proportional hazards regression, including NCS as a time&#x02010;dependent covariate and with the adjustment of baseline covariates and randomized stratification factors (Table&#x000a0;S1).</p><p>SAS software version 9.4 (SAS Institute) was used to perform statistical analyses. <italic>P</italic>&#x02010;values were not adjusted for multiple comparisons.</p></sec></sec><sec id="jah31246-sec-0009"><title>Results</title><p>In the TRACER trial, 2202 (17.0%) of 12&#x000a0;944 patients underwent NCS after randomization during a median follow&#x02010;up of 1.5&#x000a0;years. A total of 1312 (10.1%) patients underwent cardiac surgery after randomization and were excluded from the study. Baseline characteristics of patients who did and did not undergo NCS are provided in Table&#x000a0;S2. Briefly, patients who underwent NCS were more likely to be older, have a higher body mass index, have more comorbidities, and have a lower creatinine clearance and were more frequently in the vorapaxar treatment group. There were no differences between the 2 groups in revascularization strategies after the index NSTE ACS. The incidence of NCS varied by study region as follows: North America 25.8%, South America 12.6%, Western Europe 16.8%, Eastern Europe 12.8%, Asia 19.6%, and Australia/New Zealand 30.4%.</p><p>Study participants who underwent NCS were followed for a median of 565&#x000a0;days. Among the 2202 NCS procedures, 474 (21.5%) patients had major and 1728 (78.5%) had minor surgical procedures. The proportion of NCS procedures relative to the timing after the index NSTE ACS was categorized as &#x02264;30, &#x0003e;30 to 180, &#x0003e;180&#x000a0;days to 1&#x000a0;year, and &#x0003e;1&#x000a0;year and distributes as 18.5%, 30.9%, 27.2%, and 23.5%, respectively.<xref rid="jah31246-bib-0001" ref-type="ref">1</xref>, <xref rid="jah31246-bib-0016" ref-type="ref">16</xref>, <xref rid="jah31246-bib-0020" ref-type="ref">20</xref> The preoperative use of aspirin and thienopyridines was 97.2% and 87.7%, respectively, and 21.7% of patients stopped the study drug a median of 14.0 (3.0, 62.0) days preoperatively.</p><p>The baseline characteristics of NCS patients by treatment assignment are provided in Table&#x000a0;<xref rid="jah31246-tbl-0001" ref-type="table-wrap">1</xref>. Vorapaxar&#x02010; and placebo&#x02010;treated patients were well balanced by age, sex, medical history, index NSTE ACS revascularization, major versus minor surgery, and surgical timing. There were no differences in either the number of vorapaxar&#x02010; and placebo&#x02010;treated patients in whom the study drug was held preoperatively (23.1% versus 20.2%, <italic>P</italic>=0.102) or in the median times between the last study drug dose and surgery (13 versus 15&#x000a0;days, <italic>P</italic>=0.431). Vorapaxar&#x02010;treated patients were more likely to receive thienopyridines preoperatively (89.1% versus 86.1%, <italic>P</italic>=0.036). Preoperative aspirin and &#x003b2;&#x02010;blocker utilization was similar between groups. The incidences of NCS preoperative GUSTO moderate or severe (7.3% versus 4.8%, <italic>P</italic>=0.011) and TIMI clinically significant (25.4% versus 17.7%, <italic>P</italic>&#x0003c;0.001) bleeding were higher among vorapaxar&#x02010;treated NCS patients, but no treatment&#x02010;related differences were observed in the time between bleeding events and NCS.</p><table-wrap id="jah31246-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline Characteristics of NCS Patients by Treatment Assignment</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Characteristics</th><th align="left" valign="top" rowspan="1" colspan="1">Vorapaxar (n=1171)</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo (n=1031)</th><th align="left" valign="top" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, y, median (IQR)</td><td align="left" rowspan="1" colspan="1">66.0 (60.0&#x02013;74.0)</td><td align="left" rowspan="1" colspan="1">65 (59.0&#x02013;73.0)</td><td align="left" rowspan="1" colspan="1">0.073</td></tr><tr><td align="left" rowspan="1" colspan="1">Female, n (%)</td><td align="left" rowspan="1" colspan="1">335 (28.6)</td><td align="left" rowspan="1" colspan="1">96 (28.7)</td><td align="left" rowspan="1" colspan="1">0.958</td></tr><tr><td align="left" colspan="4" rowspan="1">Racial or ethics group, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="left" rowspan="1" colspan="1">1007 (86.3)</td><td align="left" rowspan="1" colspan="1">891 (86.7)</td><td align="left" rowspan="4" colspan="1">0.701</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black</td><td align="left" rowspan="1" colspan="1">29 (2.5)</td><td align="left" rowspan="1" colspan="1">25 (2.4)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asian</td><td align="left" rowspan="1" colspan="1">100 (8.6)</td><td align="left" rowspan="1" colspan="1">86 (8.4)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Other</td><td align="left" rowspan="1" colspan="1">31 (2.7)</td><td align="left" rowspan="1" colspan="1">26 (2.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body weight, kg, median (IQR)</td><td align="left" rowspan="1" colspan="1">81.0 (70.0&#x02013;94.1)</td><td align="left" rowspan="1" colspan="1">82.0 (70.5&#x02013;95.0)</td><td align="left" rowspan="1" colspan="1">0.125</td></tr><tr><td align="left" colspan="4" rowspan="1">Medical history, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">846 (72.2)</td><td align="left" rowspan="1" colspan="1">766 (74.3)</td><td align="left" rowspan="1" colspan="1">0.278</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Dyslipidemia</td><td align="left" rowspan="1" colspan="1">797 (68.1)</td><td align="left" rowspan="1" colspan="1">693 (67.2)</td><td align="left" rowspan="1" colspan="1">0.651</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" rowspan="1" colspan="1">428 (36.6)</td><td align="left" rowspan="1" colspan="1">371 (36.0)</td><td align="left" rowspan="1" colspan="1">0.783</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Current tobacco use</td><td align="left" rowspan="1" colspan="1">264 (22.5)</td><td align="left" rowspan="1" colspan="1">256 (24.8)</td><td align="left" rowspan="1" colspan="1">0.208</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Myocardial infarction</td><td align="left" rowspan="1" colspan="1">382 (32.6)</td><td align="left" rowspan="1" colspan="1">348 (33.8)</td><td align="left" rowspan="1" colspan="1">0.573</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Percutaneous coronary intervention</td><td align="left" rowspan="1" colspan="1">331 (28.3)</td><td align="left" rowspan="1" colspan="1">294 (28.5)</td><td align="left" rowspan="1" colspan="1">0.886</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Coronary artery bypass grafting</td><td align="left" rowspan="1" colspan="1">200 (17.1)</td><td align="left" rowspan="1" colspan="1">190 (18.4)</td><td align="left" rowspan="1" colspan="1">0.408</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Heart failure</td><td align="left" rowspan="1" colspan="1">157 (13.4)</td><td align="left" rowspan="1" colspan="1">168 (16.3)</td><td align="left" rowspan="1" colspan="1">0.055</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Atrial fibrillation</td><td align="left" rowspan="1" colspan="1">71 (6.1)</td><td align="left" rowspan="1" colspan="1">65 (6.3)</td><td align="left" rowspan="1" colspan="1">0.814</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke or transient ischemic attack</td><td align="left" rowspan="1" colspan="1">93 (7.9)</td><td align="left" rowspan="1" colspan="1">93 (9.0)</td><td align="left" rowspan="1" colspan="1">0.364</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Peripheral arterial disease</td><td align="left" rowspan="1" colspan="1">120 (10.2)</td><td align="left" rowspan="1" colspan="1">114 (11.1)</td><td align="left" rowspan="1" colspan="1">0.539</td></tr><tr><td align="left" colspan="4" rowspan="1">Variables at NSTE ACS presentation</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Heart rate, bpm, median (IQR)</td><td align="left" rowspan="1" colspan="1">70 (61&#x02013;80)</td><td align="left" rowspan="1" colspan="1">69 (61&#x02013;79)</td><td align="left" rowspan="1" colspan="1">0.824</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Systolic blood pressure, mm&#x000a0;Hg, median (IQR)</td><td align="left" rowspan="1" colspan="1">131 (118&#x02013;146)</td><td align="left" rowspan="1" colspan="1">130 (118&#x02013;146)</td><td align="left" rowspan="1" colspan="1">0.759</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diastolic blood pressure, mm&#x000a0;Hg, median (IQR)</td><td align="left" rowspan="1" colspan="1">72 (65&#x02013;81)</td><td align="left" rowspan="1" colspan="1">74 (65&#x02013;83)</td><td align="left" rowspan="1" colspan="1">0.235</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hemoglobin, g/L, median (IQR)</td><td align="left" rowspan="1" colspan="1">138 (126&#x02013;149)</td><td align="left" rowspan="1" colspan="1">140 (126&#x02013;150)</td><td align="left" rowspan="1" colspan="1">0.143</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Creatinine clearance, &#x003bc;mol/L, median (IQR)</td><td align="left" rowspan="1" colspan="1">87.8 (67.1&#x02013;112.2)</td><td align="left" rowspan="1" colspan="1">89.1 (66.3&#x02013;118.0)</td><td align="left" rowspan="1" colspan="1">0.115</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Positive troponin or CK&#x02010;MB, n (%)</td><td align="left" rowspan="1" colspan="1">1101 (94.4)</td><td align="left" rowspan="1" colspan="1">978 (95.2)</td><td align="left" rowspan="1" colspan="1">0.398</td></tr><tr><td align="left" style="padding-left:10%" colspan="4" rowspan="1">Electrocardiographic findings, n (%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">ST&#x02010;segment depression</td><td align="left" rowspan="1" colspan="1">353 (30.1)</td><td align="left" rowspan="1" colspan="1">296 (28.7)</td><td align="left" rowspan="1" colspan="1">0.461</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">ST&#x02010;segment elevation</td><td align="left" rowspan="1" colspan="1">60 (5.1)</td><td align="left" rowspan="1" colspan="1">44 (4.3)</td><td align="left" rowspan="1" colspan="1">0.345</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">TIMI risk score, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.520</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">0&#x02013;2</td><td align="left" rowspan="1" colspan="1">6 (0.5)</td><td align="left" rowspan="1" colspan="1">5 (0.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">3&#x02013;4</td><td align="left" rowspan="1" colspan="1">515 (44.0)</td><td align="left" rowspan="1" colspan="1">474 (46.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">5&#x02013;7</td><td align="left" rowspan="1" colspan="1">650 (55.5)</td><td align="left" rowspan="1" colspan="1">552 (53.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Killip class, n/N (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.442</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">1090/1166 (93.5)</td><td align="left" rowspan="1" colspan="1">951 (92.5)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">55/1166 (4.7)</td><td align="left" rowspan="1" colspan="1">60/1028 (5.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">III/IV</td><td align="left" rowspan="1" colspan="1">21/1166 (1.8)</td><td align="left" rowspan="1" colspan="1">17/1028 (1.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Region of enrollment, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.750</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">North America</td><td align="left" rowspan="1" colspan="1">399 (34.1)</td><td align="left" rowspan="1" colspan="1">355 (34.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">South America</td><td align="left" rowspan="1" colspan="1">50 (4.3)</td><td align="left" rowspan="1" colspan="1">38 (3.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Western Europe</td><td align="left" rowspan="1" colspan="1">467 (39.9)</td><td align="left" rowspan="1" colspan="1">427 (41.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Eastern Europe</td><td align="left" rowspan="1" colspan="1">93 (7.9)</td><td align="left" rowspan="1" colspan="1">83 (8.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asia</td><td align="left" rowspan="1" colspan="1">93 (7.9)</td><td align="left" rowspan="1" colspan="1">81 (7.9)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Australia or New Zealand</td><td align="left" rowspan="1" colspan="1">69 (5.9)</td><td align="left" rowspan="1" colspan="1">47 (4.6)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Drugs at time of NSTE ACS, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Thienopyridine</td><td align="left" rowspan="1" colspan="1">1043 (89.1)</td><td align="left" rowspan="1" colspan="1">888 (86.1)</td><td align="left" rowspan="1" colspan="1">0.036</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Aspirin</td><td align="left" rowspan="1" colspan="1">1134 (96.8)</td><td align="left" rowspan="1" colspan="1">1007 (97.7)</td><td align="left" rowspan="1" colspan="1">0.235</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x003b2;&#x02010;Blocker</td><td align="left" rowspan="1" colspan="1">889 (75.9)</td><td align="left" rowspan="1" colspan="1">805 (78.1)</td><td align="left" rowspan="1" colspan="1">0.230</td></tr><tr><td align="left" colspan="4" rowspan="1">NSTE ACS revascularization, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Medical therapy</td><td align="left" rowspan="1" colspan="1">418 (35.7)</td><td align="left" rowspan="1" colspan="1">402 (39.0)</td><td align="left" rowspan="1" colspan="1">0.186</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Bare&#x02010;metal stent</td><td align="left" rowspan="1" colspan="1">298 (25.4)</td><td align="left" rowspan="1" colspan="1">234 (22.7)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Drug&#x02010;eluting stent</td><td align="left" rowspan="1" colspan="1">455 (38.9)</td><td align="left" rowspan="1" colspan="1">395 (38.3)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Type of surgery, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Major</td><td align="left" rowspan="1" colspan="1">247 (21.1)</td><td align="left" rowspan="1" colspan="1">227 (22.0)</td><td align="left" rowspan="1" colspan="1">0.599</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Minor</td><td align="left" rowspan="1" colspan="1">924 (78.9)</td><td align="left" rowspan="1" colspan="1">804 (78.0)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Timing of surgery after randomization, d median (IQR)</td><td align="left" rowspan="1" colspan="1">180 (51&#x02013;341)</td><td align="left" rowspan="1" colspan="1">195 (61&#x02013;370)</td><td align="left" rowspan="1" colspan="1">0.053</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02264;30&#x000a0;d</td><td align="left" rowspan="1" colspan="1">226 (19.3)</td><td align="left" rowspan="1" colspan="1">181 (17.6)</td><td align="left" rowspan="1" colspan="1">0.165</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003e;30&#x000a0;d to 6&#x000a0;mo</td><td align="left" rowspan="1" colspan="1">362 (30.9)</td><td align="left" rowspan="1" colspan="1">318 (30.8)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003e;6&#x000a0;mo to 1&#x000a0;y</td><td align="left" rowspan="1" colspan="1">330 (28.2)</td><td align="left" rowspan="1" colspan="1">270 (26.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003e;1&#x000a0;y</td><td align="left" rowspan="1" colspan="1">253 (21.6)</td><td align="left" rowspan="1" colspan="1">262 (25.4)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="4" rowspan="1">Timing of surgery relative to study drug, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Surgery before last dose</td><td align="left" rowspan="1" colspan="1">901 (76.9)</td><td align="left" rowspan="1" colspan="1">819 (79.8)</td><td align="left" rowspan="1" colspan="1">0.102</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Surgery after last dose</td><td align="left" rowspan="1" colspan="1">270 (23.1)</td><td align="left" rowspan="1" colspan="1">207 (20.2)</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Time between surgery and last dose, d median (IQR)</td><td align="left" rowspan="1" colspan="1">13.0 (3.0&#x02013;52.0)</td><td align="left" rowspan="1" colspan="1">15.0 (3.0&#x02013;92.0)</td><td align="left" rowspan="1" colspan="1">0.431</td></tr></tbody></table><table-wrap-foot><fn id="jah31246-note-0002"><p>CK&#x02010;MB indicates creatinine kinase&#x02010;MB; NCS, noncardiac surgery; NSTE ACS, non&#x02013;ST&#x02010;segment elevation acute coronary syndrome; TIMI, Thrombolysis In Myocardial Infarction.</p></fn></table-wrap-foot></table-wrap><sec id="jah31246-sec-0010"><title>Outcomes of NCS Patients by Treatment Assignment</title><p>The 30&#x02010;day incidence of the primary ischemic outcome of cardiovascular mortality, nonfatal myocardial infarction, stent thrombosis, or urgent revascularization was similar in vorapaxar&#x02010; and placebo&#x02010;treated NCS patients (3.4% versus 3.9%, <italic>P</italic>=0.562). Additionally, no differences in the individual components of the 30&#x02010;day ischemic end point (Figure&#x000a0;<xref rid="jah31246-fig-0001" ref-type="fig">1</xref>; <italic>P</italic>&#x0003e;0.05 for all) or the TRACER end point (4.4% versus 4.3%, <italic>P</italic>=0.843) were observed. The primary bleeding end point of 30&#x02010;day NCS bleeding was similar for vorapaxar&#x02010; and placebo&#x02010;treated patients (3.9% versus 3.4%, <italic>P</italic>=0.507). Similarly, no differences in the incidence of all GUSTO moderate/severe, TIMI major/minor, or TIMI clinically significant bleeding were observed (<italic>P</italic>&#x0003e;0.05 for all).</p><fig fig-type="Figure" xml:lang="en" id="jah31246-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Adjusted associations between study treatment and 30&#x02010;day clinical outcomes in <styled-content style="fixed-case">NCS</styled-content> patients. No treatment&#x02010;related ischemic or bleeding differences were observed. GUSTO indicates Global Utilization of Strategies to Open Occluded Arteries; NCS, noncardiac surgery; OR, odds ratio; TIMI, Thrombolysis In Myocardial Infarction.</p></caption><graphic id="nlm-graphic-1" xlink:href="JAH3-4-e002546-g001"/></fig><p>After multivariable adjustment, the 30&#x02010;day associations between treatment assignment and the primary ischemic end point (adjusted OR 0.81, 95% CI, 0.50 to 1.33, <italic>P</italic>=0.412) (Figure&#x000a0;<xref rid="jah31246-fig-0001" ref-type="fig">1</xref>), TRACER end point (adjusted OR 1.01, 95% CI, 0.64 to 1.60, <italic>P</italic>=0.953), NCS bleeding (adjusted OR 1.41, 95% CI, 0.87 to 2.31, <italic>P</italic>=0.165), GUSTO moderate or severe bleeding (adjusted OR 1.15, 95% CI, 0.72 to 1.83, <italic>P</italic>=0.551), TIMI clinically significant bleeding (adjusted OR 1.17, 95% CI, 0.84 to 1.65, <italic>P</italic>=0.355), and TIMI major or minor bleeding (adjusted OR 1.07, 95% CI, 0.67 to 1.70, <italic>P</italic>=0.768) remained nonsignificant. In a sensitivity analysis, no differences between treatment groups in the adjusted study outcomes were observed among on&#x02010;treatment study patients (Table&#x000a0;<xref rid="jah31246-tbl-0002" ref-type="table-wrap">2</xref>). No differences in the adjusted end points were observed between vorapaxar&#x02010; versus placebo&#x02010;treated NCS patients between postoperative day 30 through the end of study follow&#x02010;up (Table&#x000a0;S3).</p><table-wrap id="jah31246-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Unadjusted and Adjusted Vorapaxar Versus Placebo 30&#x02010;Day Perioperative Outcomes in the On&#x02010;Treatment Population</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Endpoints</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Observed Events<xref ref-type="fn" rid="jah31246-note-0004">a</xref>
</th><th align="left" rowspan="2" valign="top" colspan="1">Adjusted OR (95% CI)</th><th align="left" rowspan="2" valign="top" colspan="1">
<italic>P</italic> Value</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Vorapaxar</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Primary ischemic end point</td><td align="left" rowspan="1" colspan="1">24/804 (3.0)</td><td align="left" rowspan="1" colspan="1">26/726 (3.6)</td><td align="left" rowspan="1" colspan="1">0.80 (0.44&#x02013;1.48)</td><td align="left" rowspan="1" colspan="1">0.485</td></tr><tr><td align="left" rowspan="1" colspan="1">TRACER end point</td><td align="left" rowspan="1" colspan="1">26/786 (3.3)</td><td align="left" rowspan="1" colspan="1">27/699 (3.9)</td><td align="left" rowspan="1" colspan="1">0.85 (0.47&#x02013;1.54)</td><td align="left" rowspan="1" colspan="1">0.591</td></tr><tr><td align="left" rowspan="1" colspan="1">Noncardiac surgical bleeding</td><td align="left" rowspan="1" colspan="1">30/901 (3.3)</td><td align="left" rowspan="1" colspan="1">25/819 (3.1)</td><td align="left" rowspan="1" colspan="1">1.37 (0.76&#x02013;2.45)</td><td align="left" rowspan="1" colspan="1">0.291</td></tr><tr><td align="left" rowspan="1" colspan="1">GUSTO moderate or severe bleeding</td><td align="left" rowspan="1" colspan="1">35/858 (4.1)</td><td align="left" rowspan="1" colspan="1">31/784 (4.0)</td><td align="left" rowspan="1" colspan="1">1.14 (0.66&#x02013;1.97)</td><td align="left" rowspan="1" colspan="1">0.646</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Severe bleeding</td><td align="left" rowspan="1" colspan="1">17/1146 (1.5)</td><td align="left" rowspan="1" colspan="1">12/1018 (1.2)</td><td align="left" rowspan="1" colspan="1">1.74 (0.55&#x02013;5.55)</td><td align="left" rowspan="1" colspan="1">0.350</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Moderate bleeding</td><td align="left" rowspan="1" colspan="1">34/1109 (0.7)</td><td align="left" rowspan="1" colspan="1">28/995 (2.8)</td><td align="left" rowspan="1" colspan="1">1.10 (0.59&#x02013;2.05)</td><td align="left" rowspan="1" colspan="1">0.763</td></tr><tr><td align="left" rowspan="1" colspan="1">TIMI clinically significant bleeding</td><td align="left" rowspan="1" colspan="1">80/698 (11.5)</td><td align="left" rowspan="1" colspan="1">64/679 (9.4)</td><td align="left" rowspan="1" colspan="1">1.22 (0.84&#x02013;1.78)</td><td align="left" rowspan="1" colspan="1">0.294</td></tr><tr><td align="left" rowspan="1" colspan="1">TIMI major or minor bleeding</td><td align="left" rowspan="1" colspan="1">39/850 (4.6)</td><td align="left" rowspan="1" colspan="1">28/784 (3.6)</td><td align="left" rowspan="1" colspan="1">1.22 (0.72&#x02013;2.09)</td><td align="left" rowspan="1" colspan="1">0.458</td></tr><tr><td align="left" rowspan="1" colspan="1">Intracranial haemorrhage</td><td align="left" rowspan="1" colspan="1">4/1165 (0.3)</td><td align="left" rowspan="1" colspan="1">1/1029 (0.1)</td><td align="left" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02014;</td></tr></tbody></table><table-wrap-foot><fn id="jah31246-note-0003"><p>GUSTO indicates Global Utilization of Strategies to Open Occluded Arteries; OR, odds ratio; TIMI, Thrombolysis In Myocardial Infarction; TRACER, Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome.</p></fn><fn id="jah31246-note-0004"><label>a</label><p>Denominators change with removal of presurgery events.</p></fn></table-wrap-foot></table-wrap></sec><sec id="jah31246-sec-0011"><title>Clinical Outcomes by Surgical Timing, Surgical Type, and Revascularization Strategy</title><p>The timing of surgery after NSTE ACS &#x02264;30, &#x0003e;30 to 180, &#x0003e;180&#x000a0;days to 1&#x000a0;year, and &#x0003e;1&#x000a0;year was 20.9%, 32.2%, 26.4%, and 20.5% for minor procedures and 9.7%, 26.2%, 30.2%, and 34.0% for major procedures, respectively. No significant interactions between study treatment and clinical outcomes were observed for surgical timing, revascularization strategies after the index NSTE ACS, or major versus minor surgery; thus, study treatment groups were pooled (Figure&#x000a0;<xref rid="jah31246-fig-0002" ref-type="fig">2</xref>, Table&#x000a0;S4). The adjusted 30&#x02010;day post&#x02010;NCS risk of cardiovascular mortality, nonfatal myocardial infarction, stent thrombosis, or urgent revascularization was highest among patients undergoing surgery within 30 days of the index NSTE ACS. Perioperative 30&#x02010;day NCS bleeding was numerically lower than GUSTO moderate/severe, TIMI clinically significant, or TIMI major/minor bleeding. Compared with patients undergoing NCS within 30&#x000a0;days of the index NSTE ACS, the adjusted risk of perioperative NCS bleeding was higher between &#x0003e;30 and 180&#x000a0;days, but no significant difference was observed beyond 180&#x000a0;days. The risk of TIMI clinically significant and major or minor bleeding was significantly lower in patients undergoing NCS after 30&#x000a0;days. There were no observed differences in the adjusted 30&#x02010;day risk of the primary ischemic outcome between major and minor surgeries, but the risk of 30&#x02010;day NCS&#x02010;related bleeding and GUSTO moderate or severe bleeding was higher for major surgical procedures. The risk&#x02010;adjusted 30&#x02010;day ischemic outcomes for patients who underwent revascularization with bare&#x02010;metal or drug&#x02010;eluting stents were not significantly different from those for patients who did not undergo revascularization. No relationship between study treatment, surgical site, and bleeding was observed.</p><fig fig-type="Figure" xml:lang="en" id="jah31246-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Adjusted associations of index <styled-content style="fixed-case">ACS</styled-content> management, type of <styled-content style="fixed-case">NCS</styled-content>, and surgical timing with 30&#x02010;day clinical outcomes in <styled-content style="fixed-case">NCS</styled-content> patients. <styled-content style="fixed-case">NCS</styled-content> bleeding was higher in patients who underwent major surgery and in patients who underwent surgery &#x0003c;180&#x000a0;days after <styled-content style="fixed-case">NSTE ACS</styled-content>. Ischemic events were higher in patients who underwent <styled-content style="fixed-case">NCS</styled-content> &#x0003c;30&#x000a0;days after <styled-content style="fixed-case">NSTE ACS</styled-content>. ACS indicates acute coronary syndromes; GUSTO, Global Utilization of Strategies to Open Occluded Arteries; NCS, noncardiac surgery; NSTE, non&#x02013;ST&#x02010;segment elevation; TIMI, Thrombolysis In Myocardial Infarction.</p></caption><graphic id="nlm-graphic-3" xlink:href="JAH3-4-e002546-g002"/></fig></sec><sec id="jah31246-sec-0012"><title>Long&#x02010;term Outcomes in Patients With and Without NCS</title><p>Ischemic and bleeding outcomes in NSTE ACS patients who did and did not undergo NCS are presented in Table&#x000a0;<xref rid="jah31246-tbl-0003" ref-type="table-wrap">3</xref>. No significant interactions between treatment assignment and outcomes were observed; thus, treatment groups were pooled. The median follow&#x02010;up among NCS patients (who survived through 30&#x000a0;days postoperatively) and non&#x02010;NCS patients (landmarked at 30&#x02010;day post&#x02010;NSTE ACS survival) was 1.6 and 1.3&#x000a0;years, respectively. In a 30&#x02010;day landmark analysis with NCS as a time&#x02010;dependent covariate, the adjusted ischemic end point (adjusted HR 1.62, 95% CI, 1.33 to 1.97, <italic>P</italic>&#x0003c;0.001) and the TRACER composite end point (adjusted HR 1.92, 95% CI, 1.62 to 2.27) were higher among NCS patients. The incidence of GUSTO moderate or severe bleeding (adjusted HR 5.63, 95% CI, 3.98 to 7.97, <italic>P</italic>&#x0003c;0.001) (Figure&#x000a0;<xref rid="jah31246-fig-0003" ref-type="fig">3</xref>), TIMI clinically significant bleeding (adjusted HR 3.54, 95% CI, 2.85 to 4.41, <italic>P</italic>&#x0003c;0.001), and TIMI major or minor bleeding (adjusted HR 5.19, 95% CI, 3.50 to 7.71, <italic>P</italic>&#x0003c;0.001) were all significantly higher in the NCS group. No significant interaction effect was found between the subgroups (major versus minor NCS and type of revascularization) and study treatment assignment with the ischemic and safety end points (results not shown).</p><table-wrap id="jah31246-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Outcomes in Patients With and Without NCS</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="3" valign="top" colspan="1"/><th align="left" rowspan="3" valign="top" colspan="1">Patients Without NCS (n=9363)</th><th align="left" colspan="4" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Patients With NCS (n=2202)</th><th align="left" rowspan="3" valign="top" colspan="1">
<italic>P</italic> Value<xref ref-type="fn" rid="jah31246-note-0006">a</xref>
</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1">Events Before NCS</th><th align="left" colspan="3" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Events After NCS</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Total</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02264;30&#x000a0;Days</th><th align="left" valign="top" rowspan="1" colspan="1">&#x0003e;30&#x000a0;Days</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">Clinical end points, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Primary ischemic end point</td><td align="left" rowspan="1" colspan="1">1230 (13.1)</td><td align="left" rowspan="1" colspan="1">255 (11.6)</td><td align="left" rowspan="1" colspan="1">253 (11.5)</td><td align="left" rowspan="1" colspan="1">80 (3.6)</td><td align="left" rowspan="1" colspan="1">173 (7.9)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">TRACER end point</td><td align="left" rowspan="1" colspan="1">1348 (14.4)</td><td align="left" rowspan="1" colspan="1">327 (14.9)</td><td align="left" rowspan="1" colspan="1">240 (10.9)</td><td align="left" rowspan="1" colspan="1">96 (4.4)</td><td align="left" rowspan="1" colspan="1">144 (6.5)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">All&#x02010;cause mortality</td><td align="left" rowspan="1" colspan="1">367 (3.9)</td><td align="left" rowspan="1" colspan="1">1 (0.04)</td><td align="left" rowspan="1" colspan="1">201 (9.1)</td><td align="left" rowspan="1" colspan="1">34 (1.5)</td><td align="left" rowspan="1" colspan="1">167 (7.6)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cardiovascular mortality</td><td align="left" rowspan="1" colspan="1">254 (2.7)</td><td align="left" rowspan="1" colspan="1">1 (0.04)</td><td align="left" rowspan="1" colspan="1">106 (4.8)</td><td align="left" rowspan="1" colspan="1">30 (1.4)</td><td align="left" rowspan="1" colspan="1">76 (3.4)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Myocardial infarction</td><td align="left" rowspan="1" colspan="1">819 (8.8)</td><td align="left" rowspan="1" colspan="1">237 (10.8)</td><td align="left" rowspan="1" colspan="1">146 (6.6)</td><td align="left" rowspan="1" colspan="1">68 (3.1)</td><td align="left" rowspan="1" colspan="1">78 (3.5)</td><td align="left" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stent thrombosis</td><td align="left" rowspan="1" colspan="1">77 (0.8)</td><td align="left" rowspan="1" colspan="1">25 (1.1)</td><td align="left" rowspan="1" colspan="1">11 (0.5)</td><td align="left" rowspan="1" colspan="1">6 (0.3)</td><td align="left" rowspan="1" colspan="1">5 (0.2)</td><td align="left" rowspan="1" colspan="1">0.117</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Urgent revascularization</td><td align="left" rowspan="1" colspan="1">279 (3.0)</td><td align="left" rowspan="1" colspan="1">62 (2.8)</td><td align="left" rowspan="1" colspan="1">25 (1.1)</td><td align="left" rowspan="1" colspan="1">2 (0.1)</td><td align="left" rowspan="1" colspan="1">23 (1.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Stroke</td><td align="left" rowspan="1" colspan="1">100 (1.1)</td><td align="left" rowspan="1" colspan="1">31 (1.4)</td><td align="left" rowspan="1" colspan="1">27 (1.2)</td><td align="left" rowspan="1" colspan="1">8 (0.4)</td><td align="left" rowspan="1" colspan="1">19 (0.9)</td><td align="left" rowspan="1" colspan="1">0.522</td></tr><tr><td align="left" colspan="7" rowspan="1">Safety end points, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">GUSTO moderate or severe bleeding</td><td align="left" rowspan="1" colspan="1">152 (1.6)</td><td align="left" rowspan="1" colspan="1">135 (6.1)</td><td align="left" rowspan="1" colspan="1">115 (5.2)</td><td align="left" rowspan="1" colspan="1">87 (4.0)</td><td align="left" rowspan="1" colspan="1">28 (1.3)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Severe bleeding</td><td align="left" rowspan="1" colspan="1">71 (0.8)</td><td align="left" rowspan="1" colspan="1">38 (1.7)</td><td align="left" rowspan="1" colspan="1">42 (1.9)</td><td align="left" rowspan="1" colspan="1">29 (1.3)</td><td align="left" rowspan="1" colspan="1">13 (0.6)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">Moderate bleeding</td><td align="left" rowspan="1" colspan="1">83 (0.9)</td><td align="left" rowspan="1" colspan="1">98 (4.5)</td><td align="left" rowspan="1" colspan="1">78 (3.5)</td><td align="left" rowspan="1" colspan="1">62 (2.8)</td><td align="left" rowspan="1" colspan="1">16 (0.7)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">TIMI clinically significant bleeding</td><td align="left" rowspan="1" colspan="1">850 (9.1)</td><td align="left" rowspan="1" colspan="1">480 (21.8)</td><td align="left" rowspan="1" colspan="1">236 (10.7)</td><td align="left" rowspan="1" colspan="1">173 (7.9)</td><td align="left" rowspan="1" colspan="1">63 (2.9)</td><td align="left" rowspan="1" colspan="1">0.018</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">TIMI major or minor bleeding</td><td align="left" rowspan="1" colspan="1">151 (1.6)</td><td align="left" rowspan="1" colspan="1">139 (6.3)</td><td align="left" rowspan="1" colspan="1">106 (4.8)</td><td align="left" rowspan="1" colspan="1">85 (3.9)</td><td align="left" rowspan="1" colspan="1">21 (1.0)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Intracranial haemorrhage</td><td align="left" rowspan="1" colspan="1">30 (0.3)</td><td align="left" rowspan="1" colspan="1">8 (0.4)</td><td align="left" rowspan="1" colspan="1">9 (0.4)</td><td align="left" rowspan="1" colspan="1">5 (0.2)</td><td align="left" rowspan="1" colspan="1">4 (0.2)</td><td align="left" rowspan="1" colspan="1">0.520</td></tr></tbody></table><table-wrap-foot><fn id="jah31246-note-0005"><p>GUSTO indicates Global Utilization of Strategies to Open Occluded Arteries; NCS, non cardiac surgery; TIMI, Thrombolysis In Myocardial Infarction; TRACER, Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome.</p></fn><fn id="jah31246-note-0006"><label>a</label><p>
<italic>P</italic>&#x02010;value for the comparison of patients with events after NCS vs patients without NCS.</p></fn></table-wrap-foot></table-wrap><fig fig-type="Figure" xml:lang="en" id="jah31246-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Long&#x02010;term <styled-content style="fixed-case">GUSTO</styled-content> moderate or severe bleeding in <styled-content style="fixed-case">NCS</styled-content> and non&#x02010;<styled-content style="fixed-case">NCS</styled-content> patients. Kaplan&#x02013;Meier survival estimates were obtained in patients landmarked at 30&#x000a0;days postsurgery or <styled-content style="fixed-case">NSTE ACS</styled-content>. Among 30&#x02010;day survivors, there is significant long&#x02010;term bleeding among <styled-content style="fixed-case">NCS</styled-content> patients. GUSTO, Global Utilization of Strategies to Open Occluded Arteries; HR, hazard ratio; NCS, noncardiac surgery; NSTE ACS, non&#x02013;ST&#x02010;segment elevation acute coronary syndromes.</p></caption><graphic id="nlm-graphic-5" xlink:href="JAH3-4-e002546-g003"/></fig></sec></sec><sec id="jah31246-sec-0013"><title>Discussion</title><p>In this large, contemporary, international cohort of patients undergoing NCS after an NSTE ACS with a rigorously adjudicated clinical end point, several important findings emerge. First, no significant differences were observed in the 30&#x02010;day incidence of the primary ischemic outcome or NCS bleeding between vorapaxar&#x02010; and placebo&#x02010;treated patients. Second, early NCS after an NSTE ACS was associated with a significant increase in adverse perioperative ischemic events. Our findings suggest that surgery should be delayed, where clinically appropriate, &#x02265;30&#x000a0;days to minimize ischemic events and &#x02265;6&#x000a0;months to minimize bleeding events. Finally, among 30&#x02010;day survivors, NCS patients had a significantly higher long&#x02010;term risk of ischemic events and bleeding compared with patients who did not undergo NCS, irrespective of treatment assignment.</p><p>The published incidence of NCS after an ACS or stent implantation is 2% to 34%.<xref rid="jah31246-bib-0001" ref-type="ref">1</xref>, <xref rid="jah31246-bib-0002" ref-type="ref">2</xref>, <xref rid="jah31246-bib-0003" ref-type="ref">3</xref>, <xref rid="jah31246-bib-0013" ref-type="ref">13</xref>, <xref rid="jah31246-bib-0014" ref-type="ref">14</xref>, <xref rid="jah31246-bib-0021" ref-type="ref">21</xref>, <xref rid="jah31246-bib-0022" ref-type="ref">22</xref>, <xref rid="jah31246-bib-0023" ref-type="ref">23</xref> This wide reported range in these observational analyses likely reflects differences in NCS surgical procedures (major or minor), revascularization strategies (bare&#x02010;metal and/or drug&#x02010;eluting stent), and duration of follow&#x02010;up. The present analysis, which followed both medically treated and percutaneously revascularized NSTE ACS patients for a median of 1.5&#x000a0;years, found that 17.0% of patients require major or minor NCS procedures. This finding confirms that NCS after an NSTE ACS is common in a relatively unselected population. In addition, the regional variations in the incidence of NCS after an NSTE ACS observed in this study may also provide insight into the wide difference in published NCS estimates. Our observation that Australia/New Zealand and North American had the highest NCS rates is similar to other published estimates in population&#x02010;based datasets, though this is the first study to describe international geographical differences in NCS after an NSTE ACS.<xref rid="jah31246-bib-0001" ref-type="ref">1</xref>, <xref rid="jah31246-bib-0002" ref-type="ref">2</xref>, <xref rid="jah31246-bib-0003" ref-type="ref">3</xref> Future studies may be directed at understanding the clinical and environmental reasons underpinning regional variations in the incidence of NCS.</p><p>The optimal perioperative antiplatelet management strategies in patients undergoing NCS after ACS remains unresolved. A recent major randomized trial reported that use of aspirin increased the risk of NCS bleeding, but this trial specifically excluded patients with recent coronary stenting or thienopyridine use.<xref rid="jah31246-bib-0024" ref-type="ref">24</xref> Similarly, the perioperative use of thienopyridines has been associated with increased NCS bleeding, but hemorrhagic risks must be weighed against the potential ischemic risks of drug discontinuation early after coronary stenting.<xref rid="jah31246-bib-0001" ref-type="ref">1</xref>, <xref rid="jah31246-bib-0007" ref-type="ref">7</xref>, <xref rid="jah31246-bib-0025" ref-type="ref">25</xref>, <xref rid="jah31246-bib-0026" ref-type="ref">26</xref>, <xref rid="jah31246-bib-0027" ref-type="ref">27</xref>, <xref rid="jah31246-bib-0028" ref-type="ref">28</xref> The protease&#x02010;activated receptor 1 antagonist vorapaxar had a higher incidence of bleeding in the overall trial population and, in this analysis, bleeding rates were higher among patients prior to NCS; however, vorapaxar was not associated with differences in 30&#x02010;day cardiovascular mortality, nonfatal myocardial infarction, stent thrombosis, or urgent revascularization, or 30&#x02010;day perioperative bleeding. Importantly, 78% of the patients continued vorapaxar through the perioperative period, and the results were similar in an on&#x02010;treatment sensitivity analysis. In addition, among the 22% of patients who discontinued the study drug a median of 13&#x000a0;days preoperatively, the half&#x02010;life of up to 311&#x000a0;hours suggests residual pharmacokinetic effect was likely present in many patients. These results are consistent with an animal study that reported no increase in bleeding time or blood loss with vorapaxar in addition to aspirin and thienopyridine treatment, and with the results of a secondary TRACER analysis that reported no increase in coronary artery bypass grafting&#x02013;related major bleeding.<xref rid="jah31246-bib-0015" ref-type="ref">15</xref>, <xref rid="jah31246-bib-0029" ref-type="ref">29</xref> The novel composite end point was created to best align with clinically important events in perioperative care; however, the results mirror those of the TRACER end point. Our findings have implications for patients with coronary artery disease on vorapaxar who require NCS. Among patients requiring urgent NCS, preoperative delay for the sole purpose of eliminating the drug effect is likely unnecessary. We acknowledge the need for further clarity regarding the perioperative management of other antiplatelet agents and that preoperative vorapaxar management may need to be individualized for surgical procedures where substantial morbidity with bleeding exists (ie, neurosurgery).</p><p>The association between early NCS after an ACS and adverse NCS perioperative outcomes was first described in the prerevascularization era.<xref rid="jah31246-bib-0004" ref-type="ref">4</xref>, <xref rid="jah31246-bib-0030" ref-type="ref">30</xref> A similar relationship has been well described in patients with percutaneous revascularization and has led to recommendations to delay NCS after an ACS &#x02265;30&#x000a0;days when possible.<xref rid="jah31246-bib-0001" ref-type="ref">1</xref>, <xref rid="jah31246-bib-0003" ref-type="ref">3</xref>, <xref rid="jah31246-bib-0020" ref-type="ref">20</xref>, <xref rid="jah31246-bib-0022" ref-type="ref">22</xref>, <xref rid="jah31246-bib-0025" ref-type="ref">25</xref>, <xref rid="jah31246-bib-0031" ref-type="ref">31</xref>, <xref rid="jah31246-bib-0032" ref-type="ref">32</xref>, <xref rid="jah31246-bib-0033" ref-type="ref">33</xref>, <xref rid="jah31246-bib-0034" ref-type="ref">34</xref> Our study confirms these findings using a contemporary, international cohort of patients with mixed revascularization strategies, and it suggests that surgery should be delayed &#x02265;30&#x000a0;days when it is clinically appropriate. Moreover, this analysis adds important information on perioperative bleeding. Although postoperative bleeding is associated with adverse outcomes across the spectrum of surgical procedures, little is known about its relationship with NCS timing after an NSTE ACS.<xref rid="jah31246-bib-0024" ref-type="ref">24</xref>, <xref rid="jah31246-bib-0035" ref-type="ref">35</xref>, <xref rid="jah31246-bib-0036" ref-type="ref">36</xref>, <xref rid="jah31246-bib-0037" ref-type="ref">37</xref> A recent major multicenter, randomized controlled trial reported that aspirin before NCS increased major bleeding and, in a post&#x02010;hoc analysis, major bleeding was an independent predictor of myocardial infarction.<xref rid="jah31246-bib-0024" ref-type="ref">24</xref> This trial did not, however, address the risks and benefits in patients with recent ACS. A prospective cohort of patients in France found that timing of NCS after stenting was independently associated with the risk of hemorrhagic complications.<xref rid="jah31246-bib-0027" ref-type="ref">27</xref> With the use of centrally adjudicated clinical end points, our findings suggest that, if possible, surgery should to be delayed &#x02265;6&#x000a0;months to minimize the risk of both NCS and spontaneous bleeding. Postoperative ischemic events, however, were highest within the first 30&#x000a0;days after NSTE ACS with relatively balanced events thereafter. Our findings suggest that NCS should be delayed &#x0003e;30&#x000a0;days, where clinically appropriate, to minimize the risk of both adverse cardiac events and hemorrhagic complications. Confirmation of this association with other antiplatelet agents requires further investigation.</p><p>The cardiovascular and bleeding risks of NCS after an ACS have been well described.<xref rid="jah31246-bib-0001" ref-type="ref">1</xref>, <xref rid="jah31246-bib-0038" ref-type="ref">38</xref> However, little is known about the long&#x02010;term outcomes of NCS in this population. In this study we observed a significant risk association between NCS after NSTE ACS and both ischemic events and major bleeding. Importantly, this analysis was landmarked to only include patients who survived through 30 postoperative days to minimize NCS&#x02010;related events, and the Kaplan&#x02013;Meier curves for bleeding appeared to continue to separate through the follow&#x02010;up period, suggesting a long&#x02010;term risk association between NCS and NSTE ACS that extends well beyond the traditional perioperative period. Although preoperative bleeding rates were higher among vorapaxar&#x02010;treated patients, no postoperative interaction between treatment and outcomes was observed, suggesting an independent long&#x02010;term risk association in the NCS population. We acknowledge that the reasons underpinning these findings are beyond the scope of this analysis and a careful evaluation of postoperative care may be merited on the basis of these results. Clinicians ought to carefully consider the individual patient bleeding risks and benefits before resuming antiplatelet therapies in patients with ACS who have undergone NCS.</p><sec id="jah31246-sec-0014"><title>Study Limitations</title><p>The limitations of the study merit consideration. The study case report form coded for the incidence and timing of study drug interruptions, but it did not provide detailed information on the perioperative management of aspirin, thienopyridines, or other cardiac medications. In addition, the current analysis was neither prespecified nor randomized. Thus, the results of this analysis should be considered hypothesis generating. More patients in the vorapaxar cohort of this study experienced preoperative bleeding, which influences the generalizability of the study. However, no associations between postoperative outcomes or timing of surgery were observed in this analysis. Finally, the number of patients in the major surgery cohort may not be adequately powered to detect a significant result.</p></sec></sec><sec id="jah31246-sec-0015"><title>Conclusions</title><p>Among NSTE ACS patients undergoing NCS, we observed no differences in perioperative ischemic or bleeding events between vorapaxar&#x02010; and placebo&#x02010;treated patients. Early NCS (&#x02264;30&#x000a0;days) was associated with an increased risk of adverse perioperative ischemic events and bleeding; these findings suggest that NCS should be delayed &#x02265;30&#x000a0;days to minimize ischemic events and delayed &#x02265;6&#x000a0;months to minimize bleeding. Among 30&#x02010;day NCS survivors, we observed significantly higher long&#x02010;term ischemic and bleeding risk association in patients with prior NSTE ACS. Future studies should be directed at elucidating the relationships between concurrent antiplatelet agents and revascularization strategies with clinical outcomes.</p></sec><sec id="jah31246-sec-0016"><title>Sources of Funding</title><p>The TRACER trial was funded by Merck &#x00026; Co, Inc (Whitehouse Station, NJ, USA).</p></sec><sec id="jah31246-sec-0017"><title>Disclosures</title><p>van Diepen, Podder, Westerhout, Moliterno: none. Tricoci: consultant &#x00026; research grant from Merck. Aylward: research grants from Merck, AstraZeneca, Eli Lilly, Bayer/Johnson &#x00026; Johnson, Sanofi Aventis, GalaxoSmithKline, and CSL; speaker bureau and advisory board honoraria from AstraZeneca, Eli Lilly, Boehringer Ingelheim, Bayer, Johnson &#x00026; Johnson, Pfizer, Servier, and Bristol&#x02010;Myers Squibb; travel support from Bristol&#x02010;Myers Squibb, AstraZeneca, Boehringer Ingelheim, Bayer, and Merck. Held: institutional research grants from AstraZeneca, GlaxoSmithKline, Pfizer/Bristol&#x02010;Myers Squibb, Roche, and Schering&#x02010;Plough (now Merck); consulting fees from AstraZeneca. Van de Werf: research grants, advisory board membership, and speaker's fees from Merck. Strony: employed by Merck. Wallentin: research grants from AstraZeneca, Merck &#x00026; Co, Boehringer Ingelheim, Bristol&#x02010;Myers Squibb/Pfizer, GlaxoSmithKline; consultant for Abbott, Merck &#x00026; Co, Regado Biosciences, Athera Biotechnologies, Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, and Bristol&#x02010;Myers Squibb/Pfizer; lecture fees from AstraZeneca, Boehringer Ingelheim, Bristol&#x02010;Myers Squibb/Pfizer, GlaxoSmithKline; honoraria from Boehringer Ingelheim, AstraZeneca, Bristol&#x02010;Myers Squibb/Pfizer, GlaxoSmithKline; travel support from AstraZeneca, Bristol&#x02010;Myers Squibb/Pfizer, and GSK. White: Grants from Sanofi Aventis, Eli Lilly, The Medicines Company, NIH, Roche, Merck Sharpe &#x00026; Dohme, AstraZeneca, GSK, and Daiichi Sankyo Pharma Development; nonfinancial support from AstraZeneca, non MSD, Roche, and Regado Biosciences outside the submitted work. Mahaffey: all disclosures prior to August 1, 2013 available at <ext-link ext-link-type="uri" xlink:href="http://www.dcri.org">www.dcri.org</ext-link>, and all disclosures afterward are available at <ext-link ext-link-type="uri" xlink:href="https://med.stanford.edu/profiles/kenneth-mahaffey">https://med.stanford.edu/profiles/kenneth-mahaffey</ext-link>. Harrington: research grants from Merck, AstraZeneca, Bristol&#x02010;Myers Squibb, and Johnson &#x00026; Johnson; consulting fees from CSL, Bristol&#x02010;Myers Squibb, Daiichi, Gilead, Johnson &#x00026; Johnson, Merck, and MyoKardia. Armstrong: research grants from Merck; consulting fees from Eli Lilly, and other fees from AstraZeneca. All authors have approved the final article.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data"><caption><p>
<bold>Table&#x000a0;S1.</bold> List of Adjusting Covariates for Primary and Safety End Points</p><p>
<bold>Table&#x000a0;S2.</bold> Baseline Characteristics of TRACER Patients With and Without NCS</p><p>
<bold>Table&#x000a0;S3.</bold> Unadjusted and Adjusted Vorapaxar Versus Placebo Outcomes Between Postoperative 30&#x000a0;Days Through the End of Study Follow&#x02010;up</p><p>
<bold>Table&#x000a0;S4.</bold> Thirty&#x02010;Day Clinical Outcomes by Revascularization Strategy, Major Versus Minor Surgery, and Surgical Timing</p></caption><media xlink:href="JAH3-4-e002546-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list content-type="cited-references" id="jah31246-bibl-0001"><title>References</title><ref id="jah31246-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jah31246-cit-0001">
<string-name>
<surname>Hawn</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Richman</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Itani</surname>
<given-names>KF</given-names>
</string-name>, <string-name>
<surname>Henderson</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Maddox</surname>
<given-names>TM</given-names>
</string-name>. <article-title>Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents</article-title>. <source>JAMA</source>. <year>2013</year>;<volume>310</volume>:<fpage>1462</fpage>&#x02013;<lpage>1472</lpage>.<pub-id pub-id-type="pmid">24101118</pub-id></mixed-citation></ref><ref id="jah31246-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jah31246-cit-0002">
<string-name>
<surname>To</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Webster</surname>
<given-names>MW</given-names>
</string-name>. <article-title>Noncardiac surgery and bleeding after percutaneous coronary intervention</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2009</year>;<volume>2</volume>:<fpage>213</fpage>&#x02013;<lpage>221</lpage>.<pub-id pub-id-type="pmid">20031718</pub-id></mixed-citation></ref><ref id="jah31246-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jah31246-cit-0003">
<string-name>
<surname>Wijeysundera</surname>
<given-names>DN</given-names>
</string-name>, <string-name>
<surname>Wijeysundera</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Yun</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>W&#x00105;sowicz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Beattie</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Velianou</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Ko</surname>
<given-names>DT</given-names>
</string-name>. <article-title>Risk of elective major noncardiac surgery after coronary stent insertion: a population&#x02010;based study</article-title>. <source>Circulation</source>. <year>2012</year>;<volume>126</volume>:<fpage>1355</fpage>&#x02013;<lpage>1362</lpage>.<pub-id pub-id-type="pmid">22893606</pub-id></mixed-citation></ref><ref id="jah31246-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jah31246-cit-0004">
<string-name>
<surname>Goldman</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Caldera</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Nussbaum</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Southwick</surname>
<given-names>FS</given-names>
</string-name>, <string-name>
<surname>Krogstad</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Murray</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Burke</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>O'Malley</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Goroll</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Caplan</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Nolan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Carabello</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Slater</surname>
<given-names>EE</given-names>
</string-name>. <article-title>Multifactorial index of cardiac risk in noncardiac surgical procedures</article-title>. <source>N Engl J Med</source>. <year>1977</year>;<volume>297</volume>:<fpage>845</fpage>&#x02013;<lpage>850</lpage>.<pub-id pub-id-type="pmid">904659</pub-id></mixed-citation></ref><ref id="jah31246-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jah31246-cit-0005">
<string-name>
<surname>Detsky</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Abrams</surname>
<given-names>HB</given-names>
</string-name>, <string-name>
<surname>McLaughlin</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Drucker</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Sasson</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Forbath</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hilliard</surname>
<given-names>JR</given-names>
</string-name>. <article-title>Predicting cardiac complications in patients undergoing non&#x02010;cardiac surgery</article-title>. <source>J Gen Intern Med</source>. <year>1986</year>;<volume>1</volume>:<fpage>211</fpage>&#x02013;<lpage>219</lpage>.<pub-id pub-id-type="pmid">3772593</pub-id></mixed-citation></ref><ref id="jah31246-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jah31246-cit-0006">
<string-name>
<surname>Lee</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Marcantonio</surname>
<given-names>ER</given-names>
</string-name>, <string-name>
<surname>Mangione</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Polanczyk</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Cook</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Sugarbaker</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Donaldson</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Poss</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ho</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Ludwig</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Pedan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Goldman</surname>
<given-names>L</given-names>
</string-name>. <article-title>Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery</article-title>. <source>Circulation</source>. <year>1999</year>;<volume>100</volume>:<fpage>1043</fpage>&#x02013;<lpage>1049</lpage>.<pub-id pub-id-type="pmid">10477528</pub-id></mixed-citation></ref><ref id="jah31246-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jah31246-cit-0007">
<string-name>
<surname>Capodanno</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Angiolillo</surname>
<given-names>DJ</given-names>
</string-name>. <article-title>Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery</article-title>. <source>Circulation</source>. <year>2013</year>;<volume>128</volume>:<fpage>2785</fpage>&#x02013;<lpage>2798</lpage>.<pub-id pub-id-type="pmid">24366588</pub-id></mixed-citation></ref><ref id="jah31246-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jah31246-cit-0008">
<string-name>
<surname>Burger</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Chemnitius</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Kneissl</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Rucker</surname>
<given-names>G</given-names>
</string-name>. <article-title>Low&#x02010;dose aspirin for secondary cardiovascular prevention&#x02014;cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation&#x02014;review and meta&#x02010;analysis</article-title>. <source>J Intern Med</source>. <year>2005</year>;<volume>257</volume>:<fpage>399</fpage>&#x02013;<lpage>414</lpage>.<pub-id pub-id-type="pmid">15836656</pub-id></mixed-citation></ref><ref id="jah31246-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jah31246-cit-0009">
<string-name>
<surname>Oscarsson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fredrikson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>J&#x000e4;rhult</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Nystr&#x000f6;m</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pettersson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Darvish</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Krook</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Swahn</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Eintrei</surname>
<given-names>C</given-names>
</string-name>. <article-title>To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial</article-title>. <source>Br J Anaesth</source>. <year>2010</year>;<volume>104</volume>:<fpage>305</fpage>&#x02013;<lpage>312</lpage>.<pub-id pub-id-type="pmid">20150346</pub-id></mixed-citation></ref><ref id="jah31246-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jah31246-cit-0010">
<string-name>
<surname>Mantz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Samama</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Tubach</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Devereaux</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Collet</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Albaladejo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Cholley</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Nizard</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Barr&#x000e9;</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Piriou</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Poirier</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mignon</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Schlumberger</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Longrois</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Aubrun</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Far&#x000e8;se</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Ravaud</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Steg</surname>
<given-names>PG</given-names>
</string-name>; <collab collab-type="authors">Stratagem Study Group</collab>
. <article-title>Impact of preoperative maintenance or interruption of aspirin on thrombotic and bleeding events after elective non&#x02010;cardiac surgery: the multicentre, randomized, blinded, placebo&#x02010;controlled, STRATAGEM trial</article-title>. <source>Br J Anaesth</source>. <year>2011</year>;<volume>107</volume>:<fpage>899</fpage>&#x02013;<lpage>910</lpage>.<pub-id pub-id-type="pmid">21873632</pub-id></mixed-citation></ref><ref id="jah31246-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jah31246-cit-0011">
<string-name>
<surname>Tricoci</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Held</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Moliterno</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Van de Werf</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Aylward</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lokhnygina</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Pei</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Leonardi</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rorick</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Kilian</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Jennings</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Ambrosio</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bode</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cequier</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cornel</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Diaz</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Erkan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hudson</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jukema</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Lincoff</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Montalescot</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Nicolau</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Ogawa</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pfisterer</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Prieto</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Ruzyllo</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Sinnaeve</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Storey</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Valgimigli</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Whellan</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Widimsky</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Strony</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</string-name>; <collab collab-type="authors">TRACER Investigators</collab>
. <article-title>Thrombin&#x02010;receptor antagonist vorapaxar in acute coronary syndromes</article-title>. <source>N Engl J Med</source>. <year>2012</year>;<volume>366</volume>:<fpage>20</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">22077816</pub-id></mixed-citation></ref><ref id="jah31246-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jah31246-cit-0012">
<collab collab-type="authors">TRA*CER Executive and Steering Committees</collab>
. <article-title>The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale</article-title>. <source>Am Heart J</source>. <year>2009</year>;<volume>158</volume>:<fpage>327</fpage>&#x02013;<lpage>334.e4</lpage>.<pub-id pub-id-type="pmid">19699853</pub-id></mixed-citation></ref><ref id="jah31246-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jah31246-cit-0013">
<string-name>
<surname>Berger</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Kleiman</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Pencina</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Hsieh</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Steinhubl</surname>
<given-names>SR</given-names>
</string-name>, <string-name>
<surname>Jeremias</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sonel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Browne</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Barseness</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>DJ</given-names>
</string-name>; <collab collab-type="authors">EVENT Investigators</collab>
. <article-title>Frequency of major noncardiac surgery and subsequent adverse events in the year after drug&#x02010;eluting stent placement results from the EVENT (Evaluation of Drug&#x02010;Eluting Stents and Ischemic Events) Registry</article-title>. <source>JACC Cardiovasc Interv</source>. <year>2010</year>;<volume>3</volume>:<fpage>920</fpage>&#x02013;<lpage>927</lpage>.<pub-id pub-id-type="pmid">20850090</pub-id></mixed-citation></ref><ref id="jah31246-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jah31246-cit-0014">
<string-name>
<surname>Brilakis</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Kleiman</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Pencina</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nassif</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Saucedo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Piana</surname>
<given-names>RN</given-names>
</string-name>, <string-name>
<surname>Banerjee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Keyes</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Yen</surname>
<given-names>CH</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>PB</given-names>
</string-name>. <article-title>Incidence and clinical outcome of minor surgery in the year after drug&#x02010;eluting stent implantation: results from the Evaluation of Drug&#x02010;Eluting Stents and Ischemic Events Registry</article-title>. <source>Am Heart J</source>. <year>2011</year>;<volume>161</volume>:<fpage>360</fpage>&#x02013;<lpage>366</lpage>.<pub-id pub-id-type="pmid">21315220</pub-id></mixed-citation></ref><ref id="jah31246-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jah31246-cit-0015">
<string-name>
<surname>Whellan</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Tricoci</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Leibowitz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Vranckx</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Marhefka</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Held</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Nicolau</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Storey</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Ruzyllo</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Huber</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sinnaeve</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Weiss</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Dery</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Moliterno</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Van de Werf</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Aylward</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>White</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Armstrong</surname>
<given-names>PW</given-names>
</string-name>, <string-name>
<surname>Wallentin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Strony</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Harrington</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Mahaffey</surname>
<given-names>KW</given-names>
</string-name>. <article-title>Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>63</volume>:<fpage>1048</fpage>&#x02013;<lpage>1057</lpage>.<pub-id pub-id-type="pmid">24211500</pub-id></mixed-citation></ref><ref id="jah31246-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jah31246-cit-0016">
<string-name>
<surname>Fleisher</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Beckman</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Calkins</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Chaikof</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Fleischmann</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Freeman</surname>
<given-names>WK</given-names>
</string-name>, <string-name>
<surname>Froehlich</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Kasper</surname>
<given-names>EK</given-names>
</string-name>, <string-name>
<surname>Kersten</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Riegel</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Robb</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>SC</given-names>
<suffix>Jr</suffix>
</string-name>, <string-name>
<surname>Jacobs</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>CD</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Antman</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Buller</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Creager</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Ettinger</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Faxon</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Fuster</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Halperin</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Hiratzka</surname>
<given-names>LF</given-names>
</string-name>, <string-name>
<surname>Hunt</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Lytle</surname>
<given-names>BW</given-names>
</string-name>, <string-name>
<surname>Nishimura</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ornato</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Page</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Riegel</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Tarkington</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Yancy</surname>
<given-names>CW</given-names>
</string-name>; <collab collab-type="authors">American College of Cardiology; American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery); American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery</collab>
. <article-title>ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>:<fpage>e159</fpage>&#x02013;<lpage>e241</lpage>.<pub-id pub-id-type="pmid">17950140</pub-id></mixed-citation></ref><ref id="jah31246-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jah31246-cit-0017">
<string-name>
<surname>Hammill</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Curtis</surname>
<given-names>LH</given-names>
</string-name>, <string-name>
<surname>Bennett&#x02010;Guerrero</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>O'Connor</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Jollis</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Schulman</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Hernandez</surname>
<given-names>AF</given-names>
</string-name>. <article-title>Impact of heart failure on patients undergoing major noncardiac surgery</article-title>. <source>Anesthesiology</source>. <year>2008</year>;<volume>108</volume>:<fpage>559</fpage>&#x02013;<lpage>567</lpage>.<pub-id pub-id-type="pmid">18362586</pub-id></mixed-citation></ref><ref id="jah31246-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jah31246-cit-0018">
<string-name>
<surname>Hernandez</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Whellan</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Stroud</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>O'Connor</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Jollis</surname>
<given-names>JG</given-names>
</string-name>. <article-title>Outcomes in heart failure patients after major noncardiac surgery</article-title>. <source>J Am Coll Cardiol</source>. <year>2004</year>;<volume>44</volume>:<fpage>1446</fpage>&#x02013;<lpage>1453</lpage>.<pub-id pub-id-type="pmid">15464326</pub-id></mixed-citation></ref><ref id="jah31246-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jah31246-cit-0019">
<string-name>
<surname>van Diepen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bakal</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>McAlister</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Ezekowitz</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Mortality and readmission of patients with heart failure, atrial fibrillation, or coronary artery disease undergoing noncardiac surgery: an analysis of 38&#x000a0;047 patients</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>124</volume>:<fpage>289</fpage>&#x02013;<lpage>296</lpage>.<pub-id pub-id-type="pmid">21709059</pub-id></mixed-citation></ref><ref id="jah31246-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jah31246-cit-0020">
<string-name>
<surname>Livhits</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ko</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>Leonardi</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Zingmond</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Gibbons</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>de Virgilio</surname>
<given-names>C</given-names>
</string-name>. <article-title>Risk of surgery following recent myocardial infarction</article-title>. <source>Ann Surg</source>. <year>2011</year>;<volume>253</volume>:<fpage>857</fpage>&#x02013;<lpage>864</lpage>.<pub-id pub-id-type="pmid">21372685</pub-id></mixed-citation></ref><ref id="jah31246-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jah31246-cit-0021">
<string-name>
<surname>Conroy</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bolsin</surname>
<given-names>SN</given-names>
</string-name>, <string-name>
<surname>Black</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Orford</surname>
<given-names>N</given-names>
</string-name>. <article-title>Perioperative complications in patients with drug&#x02010;eluting stents: a three&#x02010;year audit at Geelong Hospital</article-title>. <source>Anaesth Intensive Care</source>. <year>2007</year>;<volume>35</volume>:<fpage>939</fpage>&#x02013;<lpage>944</lpage>.<pub-id pub-id-type="pmid">18084986</pub-id></mixed-citation></ref><ref id="jah31246-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jah31246-cit-0022">
<string-name>
<surname>Cruden</surname>
<given-names>NL</given-names>
</string-name>, <string-name>
<surname>Harding</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Flapan</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wild</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Slack</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Pell</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Newby</surname>
<given-names>DE</given-names>
</string-name>; <collab collab-type="authors">Scottish Coronary Revascularisation Register Steering Committee</collab>
. <article-title>Previous coronary stent implantation and cardiac events in patients undergoing noncardiac surgery</article-title>. <source>Circ Cardiovasc Interv</source>. <year>2010</year>;<volume>3</volume>:<fpage>236</fpage>&#x02013;<lpage>242</lpage>.<pub-id pub-id-type="pmid">20442357</pub-id></mixed-citation></ref><ref id="jah31246-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jah31246-cit-0023">
<string-name>
<surname>Gandhi</surname>
<given-names>NK</given-names>
</string-name>, <string-name>
<surname>Abdel&#x02010;Karim</surname>
<given-names>A&#x02010;RR</given-names>
</string-name>, <string-name>
<surname>Banerjee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brilakis</surname>
<given-names>ES</given-names>
</string-name>. <article-title>Frequency and risk of noncardiac surgery after drug&#x02010;eluting stent implantation</article-title>. <source>Catheter Cardiovasc Interv</source>. <year>2011</year>;<volume>77</volume>:<fpage>972</fpage>&#x02013;<lpage>976</lpage>.<pub-id pub-id-type="pmid">20824750</pub-id></mixed-citation></ref><ref id="jah31246-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jah31246-cit-0024">
<string-name>
<surname>Devereaux</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Mrkobrada</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sessler</surname>
<given-names>DI</given-names>
</string-name>, <string-name>
<surname>Leslie</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Alonso&#x02010;Coello</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kurz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Villar</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Sigamani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Biccard</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Meyhoff</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Parlow</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Guyatt</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Robinson</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Garg</surname>
<given-names>AX</given-names>
</string-name>, <string-name>
<surname>Rodseth</surname>
<given-names>RN</given-names>
</string-name>, <string-name>
<surname>Botto</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Lurati Buse</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Xavier</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Tiboni</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cook</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Forget</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Malaga</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fleischmann</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Amir</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Eikelboom</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mizera</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Torres</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>CY</given-names>
</string-name>, <string-name>
<surname>VanHelder</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Paniagua</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Berwanger</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Srinathan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pasin</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Le Manach</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pogue</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Whitlock</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lamy</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kearon</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Baigent</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chow</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Pettit</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chrolavicius</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yusuf</surname>
<given-names>S</given-names>
</string-name>; <collab collab-type="authors">POISE&#x02010;2 Investigators</collab>
. <article-title>Aspirin in patients undergoing noncardiac surgery</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>370</volume>:<fpage>1494</fpage>&#x02013;<lpage>1503</lpage>.<pub-id pub-id-type="pmid">24679062</pub-id></mixed-citation></ref><ref id="jah31246-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jah31246-cit-0025">
<string-name>
<surname>Howard&#x02010;Alpe</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>de Bono</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hudsmith</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Orr</surname>
<given-names>WP</given-names>
</string-name>, <string-name>
<surname>Foex</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sear</surname>
<given-names>JW</given-names>
</string-name>. <article-title>Coronary artery stents and non&#x02010;cardiac surgery</article-title>. <source>Br J Anaesth</source>. <year>2007</year>;<volume>98</volume>:<fpage>560</fpage>&#x02013;<lpage>574</lpage>.<pub-id pub-id-type="pmid">17456488</pub-id></mixed-citation></ref><ref id="jah31246-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jah31246-cit-0026">
<string-name>
<surname>Ernst</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Eberhardt</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wahidi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>HD</given-names>
</string-name>, <string-name>
<surname>Herth</surname>
<given-names>FJ</given-names>
</string-name>. <article-title>Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans</article-title>. <source>Chest</source>. <year>2006</year>;<volume>129</volume>:<fpage>734</fpage>&#x02013;<lpage>737</lpage>.<pub-id pub-id-type="pmid">16537875</pub-id></mixed-citation></ref><ref id="jah31246-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jah31246-cit-0027">
<string-name>
<surname>Albaladejo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Marret</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Samama</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Collet</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Abhay</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Loutrel</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Charbonneau</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Jaber</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Thoret</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bosson</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Piriou</surname>
<given-names>V</given-names>
</string-name>. <article-title>Non&#x02010;cardiac surgery in patients with coronary stents: the RECO study</article-title>. <source>Heart</source>. <year>2011</year>;<volume>97</volume>:<fpage>1566</fpage>&#x02013;<lpage>1572</lpage>.<pub-id pub-id-type="pmid">21791513</pub-id></mixed-citation></ref><ref id="jah31246-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jah31246-cit-0028">
<string-name>
<surname>Vicenzi</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Meislitzer</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Heitzinger</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Halaj</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fleisher</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Metzler</surname>
<given-names>H</given-names>
</string-name>. <article-title>Coronary artery stenting and non&#x02010;cardiac surgery&#x02013;a prospective outcome study</article-title>. <source>Br J Anaesth</source>. <year>2006</year>;<volume>96</volume>:<fpage>686</fpage>&#x02013;<lpage>693</lpage>.<pub-id pub-id-type="pmid">16670113</pub-id></mixed-citation></ref><ref id="jah31246-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jah31246-cit-0029">
<string-name>
<surname>Chintala</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vemulapalli</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kurowski</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sabin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Reynolds</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Prevete</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Friedrichs</surname>
<given-names>G</given-names>
</string-name>. <article-title>SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys</article-title> (abstract P579). <source>Arterioscler Thromb Vasc Biol</source>. <year>2008</year>;<volume>28</volume>:<fpage>e138</fpage>&#x02013;<lpage>e139</lpage>. Available at: <ext-link ext-link-type="uri" xlink:href="http://atvb.ahajournals.org/content/28/6/e32.full.pdf+html">http://atvb.ahajournals.org/content/28/6/e32.full.pdf+html</ext-link>. Accessed May 21, 2014.</mixed-citation></ref><ref id="jah31246-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jah31246-cit-0030">
<string-name>
<surname>Rao</surname>
<given-names>TL</given-names>
</string-name>, <string-name>
<surname>Jacobs</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>El&#x02010;Etr</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Reinfarction following anesthesia in patients with myocardial infarction</article-title>. <source>Anesthesiology</source>. <year>1983</year>;<volume>59</volume>:<fpage>499</fpage>&#x02013;<lpage>505</lpage>.<pub-id pub-id-type="pmid">6650905</pub-id></mixed-citation></ref><ref id="jah31246-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jah31246-cit-0031">
<string-name>
<surname>Ka&#x00142;uza</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Joseph</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Raizner</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Raizner</surname>
<given-names>AE</given-names>
</string-name>. <article-title>Catastrophic outcomes of noncardiac surgery soon after coronary stenting</article-title>. <source>J Am Coll Cardiol</source>. <year>2000</year>;<volume>35</volume>:<fpage>1288</fpage>&#x02013;<lpage>1294</lpage>.<pub-id pub-id-type="pmid">10758971</pub-id></mixed-citation></ref><ref id="jah31246-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jah31246-cit-0032">
<string-name>
<surname>Wilson</surname>
<given-names>SH</given-names>
</string-name>, <string-name>
<surname>Fasseas</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Orford</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Lennon</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Horlocker</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Charnoff</surname>
<given-names>NE</given-names>
</string-name>, <string-name>
<surname>Melby</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Berger</surname>
<given-names>PB</given-names>
</string-name>. <article-title>Clinical outcome of patients undergoing non&#x02010;cardiac surgery in the two months following coronary stenting</article-title>. <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>42</volume>:<fpage>234</fpage>&#x02013;<lpage>240</lpage>.<pub-id pub-id-type="pmid">12875757</pub-id></mixed-citation></ref><ref id="jah31246-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jah31246-cit-0033">
<string-name>
<surname>Reddy</surname>
<given-names>PR</given-names>
</string-name>, <string-name>
<surname>Vaitkus</surname>
<given-names>PT</given-names>
</string-name>. <article-title>Risks of noncardiac surgery after coronary stenting</article-title>. <source>Am J Cardiol</source>. <year>2005</year>;<volume>95</volume>:<fpage>755</fpage>&#x02013;<lpage>757</lpage>.<pub-id pub-id-type="pmid">15757604</pub-id></mixed-citation></ref><ref id="jah31246-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jah31246-cit-0034">
<string-name>
<surname>Holcomb</surname>
<given-names>CN</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Richman</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Rhyne</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Itani</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Maddox</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Hawn</surname>
<given-names>MT</given-names>
</string-name>. <article-title>The incremental risk of noncardiac surgery on adverse cardiac events following coronary stenting</article-title>. <source>J Am Coll Cardiol</source>. <year>2014</year>;<volume>64</volume>:<fpage>2730</fpage>&#x02013;<lpage>2739</lpage>.<pub-id pub-id-type="pmid">25541124</pub-id></mixed-citation></ref><ref id="jah31246-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jah31246-cit-0035">
<string-name>
<surname>Johnston</surname>
<given-names>KW</given-names>
</string-name>. <article-title>Multicenter prospective study of nonruptured abdominal aortic aneurysm. Part II. Variables predicting morbidity and mortality</article-title>. <source>J Vasc Surg</source>. <year>1989</year>;<volume>9</volume>:<fpage>437</fpage>&#x02013;<lpage>447</lpage>.<pub-id pub-id-type="pmid">2646460</pub-id></mixed-citation></ref><ref id="jah31246-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jah31246-cit-0036">
<string-name>
<surname>Mor</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Jennings</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gonwa</surname>
<given-names>TA</given-names>
</string-name>, <string-name>
<surname>Holman</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Gibbs</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Solomon</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Goldstein</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Husberg</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Watemberg</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Klintmalm</surname>
<given-names>GB</given-names>
</string-name>. <article-title>The impact of operative bleeding on outcome in transplantation of the liver</article-title>. <source>Surg Gynecol Obstet</source>. <year>1993</year>;<volume>176</volume>:<fpage>219</fpage>&#x02013;<lpage>227</lpage>.<pub-id pub-id-type="pmid">8438192</pub-id></mixed-citation></ref><ref id="jah31246-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jah31246-cit-0037">
<string-name>
<surname>Moulton</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Creswell</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Mackey</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Cox</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Rosenbloom</surname>
<given-names>M</given-names>
</string-name>. <article-title>Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>1996</year>;<volume>111</volume>:<fpage>1037</fpage>&#x02013;<lpage>1046</lpage>.<pub-id pub-id-type="pmid">8622301</pub-id></mixed-citation></ref><ref id="jah31246-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jah31246-cit-0038">
<string-name>
<surname>Douketis</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Spyropoulos</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Spencer</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Mayr</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jaffer</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Eckman</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Dunn</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Kunz</surname>
<given-names>R</given-names>
</string-name>; <collab collab-type="authors">American College of Chest Physicians</collab>
. <article-title>Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence&#x02010;Based Clinical Practice Guidelines</article-title>. <source>Chest</source>. <year>2012</year>;<volume>141</volume>:<fpage>e326S</fpage>&#x02013;<lpage>e350S</lpage>.<pub-id pub-id-type="pmid">22315266</pub-id></mixed-citation></ref></ref-list></back></article>